Open Biosystems was founded in 2001 by a team of researchers who believe deeply in the power of science to improve all of our lives. Their business model, based on a collaborative spirit and focused on the value of product delivery, is inspired by the success of the open source movement in software. Open source has, over the span of just a few years, radically empowered small organizations and individuals by giving them the tools only big companies could previously afford.
Genomics, RNAi and Antibodies - Open Biosystems offers products that span all of these areas. Delivery of genetic content is their most recent technological breakthrough with the unique Tranz-vector system, the safest human-based lentiviral delivery technology. Further supplementing their already strong line of RNA interference (RNAi) and complementary DNA (cDNA) products, this technology provides investigators with superior delivery capabilities for high-quality cellular screening, enabling drug target validation on a large scale.
Open Biosystems offer the most complete gene library in the industry consisting of several full length cDNA and open reading frame collections. Most prominently among these is the Mammalian Gene Collection (MGC), the industry�s gold standard gene catalogue.
The discovery of RNA interference has revolutionized the way investigators approach the studies of gene expression, regulation and interactions, particularly as it relates to drug development. Their collaboration with Drs. Greg Hannon (CSHL) and Steve Elledge (Harvard) has led the way in the evolution of the short hairpin RNA (shRNA) technologies to provide the life science community with whole genome resources for human, mouse and rat with a multitude of technology and delivery advantages.
